Breaks Categories: News

MondayJul 31, 2017 8:56 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Announces Establishment of Hemp Education Center

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that its wholly-owned subsidiary, ChineseHempOil.com, Inc., has established a Hemp Education Center in San Gabriel, California. Through this club-style education center, the company aims to provide valuable information to those who want to learn more about the potential health benefits of non-industrial hemp and hemp-derived cannabidiol (CBD). “I am delighted about the possibilities of our new Hemp Education Center,” Warren Wang, CEO and founder of CIIX, stated in the news release. “In recognition of the unprecedented opportunities in the legal non-industrial hemp industry, CIIX expanded its business to capitalize on…

Continue Reading

FridayJul 28, 2017 1:09 pm

NetworkNewsBreaks – Windstream Holdings, Inc. (NASDAQ: WIN) Acquires Broadview Networks

Windstream Holdings (NASDAQ: WIN) has completed its acquisition of Broadview Networks Holdings, Inc. The company previously announced the $227.5 million all-cash transaction in April 2017. Additionally, the company announced that Brian Crotty, chief operating officer of Broadview, has been named president of the mid-market and small business division. Various other members of Broadview’s management team have also been added to the small business division. “The addition of Broadview advances our strategy to differentiate ourselves by delivering a truly superior customer experience using disruptive technologies,” Windstream president and chief executive officer Tony Thomas stated in the news release. To view the…

Continue Reading

FridayJul 28, 2017 12:15 pm

NetworkNewsBreaks – Cesca Therapeutics, Inc. (NASDAQ: KOOL) Shares Tick Higher on Issuance of New Cellular Processing Methodology Patent

Cesca Therapeutics (NASDAQ: KOOL) shares are up 7% mid-day on news that SynGen, Inc. (whose cell processing assets were acquired by Cesca’s 80%-owned subsidiary ThermoGenesis Corp.) has been awarded a new patent entitled “Cell Separation Devices, Systems, and Methods” by the U.S. Patent and Trademark Office. The patent covers a device and methodology for integrating automated cellular separation and buoyancy-activated cell sorting processes. “This new patent issuance significantly strengthens the intellectual property position surrounding our proprietary automation technology which is core to our best-in-class ThermoGenesis portfolio of cell processing systems,” Cesca CEO Chris Xu stated in the news release. To…

Continue Reading

FridayJul 28, 2017 9:22 am

NetworkNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Moves Closer to Kimmett Expansion with TSXV Approval of Cannabis Wheaton Investment

Cannabis Wheaton Income Corp. (TSX.V: CBW) this morning announced that it has received approval from the TSX Venture Exchange to purchase $15 million of common shares of ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) at an agreed upon valuation of $2.25 per share. Per the update, this investment forms a portion of a larger phased investment by Cannabis Wheaton aimed at funding the construction of ABcann’s proposed 50,000 square foot addition to its Kimmett cannabis cultivation facility to be located in Napanee, Ontario. This morning’s announcement follows the two companies’ entry into a binding interim agreement on May 29, 2017,…

Continue Reading

ThursdayJul 27, 2017 12:30 pm

NetworkNewsBreaks – Cerus Corp. (NASDAQ: CERS) Partners with Central California Blood Center to Manufacture Pathogen-Reduced Cryoprecipitate

Shares of Cerus (NASDAQ: CERS) are up 15% following news of the company's agreement with the Central California Blood Center (CCBC). CCBC will manufacture for Cerus a pathogen-reduced cryoprecipitate (cryo), a blood product used in the control of bleeding associated with acquired fibrinogen deficiency. “Cryo is a natural extension to our current FDA-approved INTERCEPT Blood System for Plasma. Following approval of a proposed premarket approval (PMA) supplement, INTERCEPT Plasma may be further manufactured into cryoprecipitate, for which we plan to seek an extended 5-day post-thaw storage claim. Given today’s growing emphasis on, and use of, coagulation monitoring and fibrinogen supplementation…

Continue Reading

ThursdayJul 27, 2017 12:27 pm

NetworkNewsBreaks – Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) Says Cigna will Cover ThyGenX® Nationwide

Interpace Diagnostics Group (NASDAQ: IDXG) has entered an agreement with Cigna to provide coverage of the company’s ThyGenX® test, effective immediately. Cigna is one of the largest national health plans in the United States, with 15 million members nationwide. This new agreement brings the number of individuals covered for Interpace’s ThyGenX™ molecular test for indeterminate thyroid nodules to approximately 275 million patients nationwide. “Cigna’s coverage of ThyGenX represents further acceptance among major health plans of our molecular products for Thyroid cancer.  We are pleased that Cigna has joined the growing list of health plans that cover ThyGenX and that their…

Continue Reading

ThursdayJul 27, 2017 12:22 pm

NetworkNewsBreaks – Capricor Therapeutics, Inc. (NASDAQ: CAPR) Shares Surge on Details of Recent Meeting with FDA Regarding Intravenous CAP-1002

Capricor Therapeutics (NASDAQ: CAPR) shares are up 30% after the company said the U.S. FDA has indicated it is willing to accept the company’s proposal to use the Performance of the Upper Limb as the basis for the primary efficacy endpoint for clinical studies of CAP-1002 for the treatment of muscular dystrophy. Official minutes from the company's recent meeting with the regulatory agency also show support for submission of an Investigational New Drug (IND) application to clinically evaluate repeat intravenous administration of CAP-1002. "The FDA's response to our proposed clinical development plan supports our near-term objective of submitting an IND…

Continue Reading

ThursdayJul 27, 2017 9:23 am

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Research Published in the European Journal of Pain

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the publication of company-sponsored research in the European Journal of Pain. The article, titled ‘Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation’, highlights results from a study co-sponsored by InMed and the MITACS Elevate Postdoctoral Fellowship Program. “Developing a topically-applied product that can provide localized relief of chronic and/or acute severe pain, without central side effects, remains one of the 'holy grails' in the field of analgesia,” Dr. Sazzad Hossain, chief scientific officer of InMed, stated in the news release. “This…

Continue Reading

WednesdayJul 26, 2017 2:46 pm

NetworkNewsBreaks – InfoSonics Corp. (NASDAQ: IFON) Enters Definitive Merger Agreement to Acquire Cooltech Holding Corp.; Shares Higher

InfoSonics (NASDAQ: IFON) is trading 39% higher following early news of the company’s definitive merger agreement to acquire Cooltech Holding Corp. Cooltech is an Apple licensed partner and reseller that operates as a vertically integrated company combining a distribution business with a growing retail footprint under its OneClick branded stores. Cooltech will become a wholly owned subsidiary of InfoSonics in exchange for 62.5 million shares of InfoSonics common stock upon closing of the merger transaction. The company expects to close the transaction in the fourth quarter of 2017, subject to approval by InfoSonics’ shareholders. "We believe this merger represents an…

Continue Reading

WednesdayJul 26, 2017 1:01 pm

NetworkNewsBreaks – Argos Therapeutics, Inc. (NASDAQ: ARGS) Shares Soar on Immunogenicity Data from AGS-004 in HIV Program

Argos Therapeutics (NASDAQ: ARGS) shares jumped more than 17% this morning on the company’s report of immunogenicity data from a study of AGS-004 dendritic cell therapy in patients treated during acute HIV infection. AGS-004 is an autologous cell therapy manufactured using the Arcelis® precision immunotherapy technology platform. During the open label study conducted at the University of North Carolina and Duke University, AGS-004 was produced on an individual basis for each patient. The study achieved its primary endpoint, with all six patients demonstrating a positive immune response. These data were recently published in the Journal of AIDS Research and Human…

Continue Reading